Advertisement

Archives of Gynecology and Obstetrics

, Volume 284, Issue 3, pp 699–704 | Cite as

Significance of PTPRZ1 and CIN85 expression in cervical carcinoma

  • Yaxi Ma
  • Feng Ye
  • Xing Xie
  • Caiyun Zhou
  • Weiguo Lu
Gynecologic Oncology

Abstract

Purpose

To investigate PTPRZ1 and CIN85 expression and their significance in cervical carcinoma.

Methods

The expression of PTPRZ1 and CIN85 was detected by immunohistochemistry and the association between PTPRZ1 and CIN85 expression and clinical pathological variables were analyzed.

Results

The expression of PTPRZ1 and CIN85 were significantly higher in cervical carcinoma than those in normal cervical epithelium. CIN85 expression was significantly higher in patients with deeper cervical invasion when compared with that with superficial invasion, while PTPRZ1 expression was significantly higher in patients with smaller tumor size (≤2 cm) than that with larger size (>2 cm). The expression of PTPRZ1 and CIN85 were higher in squamous cell carcinoma than those in adenocarcinoma.

Conclusions

There exist increased PTPRZ1 and CIN85 expression in cervical carcinoma and they are probably associated with tumor growth or invasion. PTPRZ1 and CIN85 expression were higher in squamous cell carcinoma than those in adenocarcinoma.

Keywords

Gynae-oncology PTPRZ1 CIN85 Cervical carcinoma 

Notes

Acknowledgments

This work was supported by the Scientific Research Foundation of Education Department of Zhejiang Province, China (Y200908905), Scientific Research Foundation of Ministry of Health, China (wkj2007-2-014) and the Nature Science Foundation of China (30872752).

Conflict of interest

We declare that we have no conflict of interest.

References

  1. 1.
    Barnea G, Grumet M, Milev P, Silvennoinen O, Levy JB, Sap J et al (1994) Receptor tyrosine phosphatase β is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. J Biol Chem 269(20):14349–14352PubMedGoogle Scholar
  2. 2.
    Yamakawa T, Kurosawa N, Kadomatsu K, Matsui T, Itoh K, Maeda N (1999) Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers. Cancer Lett 135(1):91–96PubMedCrossRefGoogle Scholar
  3. 3.
    Foehr ED, Lorente G, Kuo J, Ram R, Nikolich K, Urfer R (2006) Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 66(4):2271–2278PubMedCrossRefGoogle Scholar
  4. 4.
    Wu CW, Kao HL, Li AF, Chi CW, Lin WC (2006) Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett 242(1):95–103PubMedCrossRefGoogle Scholar
  5. 5.
    Goldmann T, Otto F, Vollmer E (2000) A receptor-type protein tyrosine phosphatase PTP zeta is expressed in human cutaneous melanomas. Folia Histochem Cytobiol 38(1):19–20PubMedGoogle Scholar
  6. 6.
    Ulbricht U, Brockmann MA, Aigner A, Eckerich C, Müller S, Fillbrandt R et al (2003) Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol 62(12):1265–1275PubMedGoogle Scholar
  7. 7.
    Dikic I (2002) CIN85/CMS family of adaptor molecules. FEBS Lett 529(1):110–115 (review)PubMedCrossRefGoogle Scholar
  8. 8.
    Dikic I, Giordano S (2003) Negative receptor signalling. Curr Opin Cell Biol 15(2):128–135 (review)PubMedCrossRefGoogle Scholar
  9. 9.
    Szymkiewicz I, Kowanetz K, Soubeyran P, Dinarina A, Lipkowitz S, Dikic I (2002) CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine kinases. J Biol Chem 277(42):39666–39672PubMedCrossRefGoogle Scholar
  10. 10.
    Bögler O, Furnari FB, Kindler-Roehrborn A, Sykes VW, Yung R, Huang HJ et al (2000) SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro Oncol 2(1):6–15PubMedGoogle Scholar
  11. 11.
    Mayevska O, Shuvayeva H, Igumentseva N, Havrylov S, Basaraba O, Bobak Y et al (2006) Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma. Exp Oncol 28(4):275–281PubMedGoogle Scholar
  12. 12.
    Havrylov S, Rzhepetskyy Y, Malinowska A, Drobot L, Redowicz MJ (2009) Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC–MS/MS. Proteome Sci 7(1):21PubMedCrossRefGoogle Scholar
  13. 13.
    Petereit DG, Eifel PJ, Thomas GM (2007) Cervical cancer. In: Gunderson LL, Tepper JE (eds) Clinical radiation oncology, 2nd edn. Churchill Livingstone, Philadelphia, pp 1323–1357Google Scholar
  14. 14.
    Gadducci A, Teti G, Barsotti C, Tana R, Fanucchi A, Orlandini C et al (2010) Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. Anticancer Res 30(1):201–208PubMedGoogle Scholar
  15. 15.
    Meng K, Rodriguez-Peña A, Dimitrov T, Chen W, Yamin M, Noda M et al (2000) Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA 97(6):2603–2608PubMedCrossRefGoogle Scholar
  16. 16.
    Wu M, Gan K, Huang C, Tang Y, Chen Q, Tang K et al (2006) LRRC4 controls in vitro invasion of glioblastoma cells through inhibiting RPTP-zeta expression. J Neurooncol 80(2):133–142PubMedCrossRefGoogle Scholar
  17. 17.
    Nagata S, Saito R, Yamada Y, Fujita N, Watanabe K (2001) Multiple variants of receptor-type protein tyrosine phosphatase beta are expressed in the central nervous system of Xenopus. Gene 262(1–2):81–88PubMedCrossRefGoogle Scholar
  18. 18.
    Levy JB, Canoll PD, Silvennoinen O, Barnea G, Morse B, Honegger AM et al (1993) The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J Biol Chem 268(14):10573–10581PubMedGoogle Scholar
  19. 19.
    Lorente G, Nelson A, Mueller S, Kuo J, Urfer R, Nikolich K et al (2005) Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment. Neuro Oncol 7(2):154–163PubMedCrossRefGoogle Scholar
  20. 20.
    Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K (2006) RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem 98(5):1497–1506PubMedCrossRefGoogle Scholar
  21. 21.
    Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K et al (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 280(29):26953–26964PubMedCrossRefGoogle Scholar
  22. 22.
    Perez-Pinera P, Garcia-Suarez O, Menendez-Rodriguez P, Mortimer J, Chang Y, Astudillo A et al (2007) The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun 362(1):5–10PubMedCrossRefGoogle Scholar
  23. 23.
    Nam JM, Onodera Y, Mazaki Y, Miyoshi H, Hashimoto S, Sabe H (2007) CIN85, a Cbl-interacting protein, is a component of AMAP1-mediated breast cancer invasion machinery. EMBO J 26(3):647–656PubMedCrossRefGoogle Scholar
  24. 24.
    Gaidos G, Soni S, Oswald DJ, Toselli PA, Kirsch KH (2007) Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic–complex formation. J Cell Sci 120(14):2366–2377PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yaxi Ma
    • 1
  • Feng Ye
    • 2
  • Xing Xie
    • 2
  • Caiyun Zhou
    • 2
  • Weiguo Lu
    • 2
  1. 1.Department of Gynecology, The Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China
  2. 2.Department of Gynecologic Oncology, The Women’s Hospital, School of MedicineZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations